It is another significant deal from Glenmark Pharma. This time it is extending its earlier partnership with Sanofi Aventis for a second molecule for $613 million with upfront payments of $50 million. New molecule GBR 500 is being developed for auto immune diseases and is expected to be commercialised by 2017.
